GÜVENİR ÇELİK, E. And EROĞLU, O. 2023. Combined treatment with ruxolitinib and MK-2206 inhibits the JAK2/STAT5 and PI3K/AKT pathways via apoptosis in MDA-MB-231 breast cancer cell line. Molecular Biology Reports , vol.50, no.1 , 319-329.

GÜVENİR ÇELİK, E., & EROĞLU, O., (2023). Combined treatment with ruxolitinib and MK-2206 inhibits the JAK2/STAT5 and PI3K/AKT pathways via apoptosis in MDA-MB-231 breast cancer cell line. Molecular Biology Reports , vol.50, no.1, 319-329.

GÜVENİR ÇELİK, ESİN, And ONUR EROĞLU. "Combined treatment with ruxolitinib and MK-2206 inhibits the JAK2/STAT5 and PI3K/AKT pathways via apoptosis in MDA-MB-231 breast cancer cell line," Molecular Biology Reports , vol.50, no.1, 319-329, 2023

GÜVENİR ÇELİK, ESİN G. And EROĞLU, ONUR. "Combined treatment with ruxolitinib and MK-2206 inhibits the JAK2/STAT5 and PI3K/AKT pathways via apoptosis in MDA-MB-231 breast cancer cell line." Molecular Biology Reports , vol.50, no.1, pp.319-329, 2023

GÜVENİR ÇELİK, E. And EROĞLU, O. (2023) . "Combined treatment with ruxolitinib and MK-2206 inhibits the JAK2/STAT5 and PI3K/AKT pathways via apoptosis in MDA-MB-231 breast cancer cell line." Molecular Biology Reports , vol.50, no.1, pp.319-329.

@article{article, author={ESİN GÜVENİR ÇELİK And author={ONUR EROĞLU}, title={Combined treatment with ruxolitinib and MK-2206 inhibits the JAK2/STAT5 and PI3K/AKT pathways via apoptosis in MDA-MB-231 breast cancer cell line}, journal={Molecular Biology Reports}, year=2023, pages={319-329} }